248 related articles for article (PubMed ID: 32485203)
1. Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review.
Grabski M; Borissova A; Marsh B; Morgan CJA; Curran HV
Behav Brain Res; 2020 Aug; 392():112629. PubMed ID: 32485203
[TBL] [Abstract][Full Text] [Related]
2. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
3. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
[No Abstract] [Full Text] [Related]
4. Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.
McMullen EP; Lee Y; Lipsitz O; Lui LMW; Vinberg M; Ho R; Rodrigues NB; Rosenblat JD; Cao B; Gill H; Teopiz KM; Cha DS; McIntyre RS
Adv Ther; 2021 Jun; 38(6):2795-2820. PubMed ID: 33929660
[TBL] [Abstract][Full Text] [Related]
5. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
Niciu MJ; Shovestul BJ; Jaso BA; Farmer C; Luckenbaugh DA; Brutsche NE; Park LT; Ballard ED; Zarate CA
J Affect Disord; 2018 May; 232():310-315. PubMed ID: 29501990
[TBL] [Abstract][Full Text] [Related]
6. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.
van Schalkwyk GI; Wilkinson ST; Davidson L; Silverman WK; Sanacora G
J Affect Disord; 2018 Feb; 227():11-16. PubMed ID: 29045915
[TBL] [Abstract][Full Text] [Related]
7. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
8. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review.
Mathai DS; Meyer MJ; Storch EA; Kosten TR
J Affect Disord; 2020 Mar; 264():123-129. PubMed ID: 32056741
[TBL] [Abstract][Full Text] [Related]
9. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study.
Włodarczyk A; Cubała WJ; Gałuszko-Węgielnik M; Szarmach J
Medicine (Baltimore); 2021 Jul; 100(29):e26769. PubMed ID: 34398056
[TBL] [Abstract][Full Text] [Related]
10. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
12. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
Ng J; Rosenblat JD; Lui LMW; Teopiz KM; Lee Y; Lipsitz O; Mansur RB; Rodrigues NB; Nasri F; Gill H; Cha DS; Subramaniapillai M; Ho RC; Cao B; McIntyre RS
J Affect Disord; 2021 Oct; 293():285-294. PubMed ID: 34225208
[TBL] [Abstract][Full Text] [Related]
14. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).
Kwan ATH; Rosenblat JD; Mansur RB; Teopiz KM; McIntyre RS
J Affect Disord; 2024 Sep; 360():421-426. PubMed ID: 38795777
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
16. Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh DA; Niciu MJ; Ionescu DF; Nolan NM; Richards EM; Brutsche NE; Guevara S; Zarate CA
J Affect Disord; 2014 Apr; 159():56-61. PubMed ID: 24679390
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
Kryst J; Kawalec P; Pilc A
Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
[No Abstract] [Full Text] [Related]
18. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
Sukhram SD; Yilmaz G; Gu J
Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
[TBL] [Abstract][Full Text] [Related]
20. Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study.
Glue P; Neehoff S; Beaglehole B; Shadli S; McNaughton N; Hughes-Medlicott NJ
J Psychopharmacol; 2024 Feb; 38(2):162-167. PubMed ID: 38293803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
